Table 4. Rate and Rate Ratios of CDA.
| Variables | Group | Total CDA | Total PY | CDA rate | Unadjusted RR (95% CI), P-value | Adjusted RR (95% CI), P-value |
|---|---|---|---|---|---|---|
| By ASCA-IgA | ||||||
| Antibody ASCA-IgA (binary variable) | Low, 70 | 42 | 100 | 0.42 (0.31 - 0.57) | ||
| High, 65 | 42 | 104 | 0.40 (0.30 - 0.55) | 0.96 (0.63 - 1.47), 0.8480 | 0.83 (0.53 - 1.31), 0.4317a | |
| ASCA-IgA1 (10 units increase) | 1.01 (0.95 - 1.06), 0.8004 | 0.99 (0.94 - 1.05), 0.8247a | ||||
| By ASCA-IgG | ||||||
| Antibody ASCA-IgG (binary variable) | Low, 76 | 46 | 113 | 0.41 (0.31 - 0.54) | ||
| High, 59 | 38 | 91 | 0.42 (0.31 - 0.58) | 1.03 (0.67 - 1.58), 0.8956 | 1.09 (0.66 - 1.79), 0.7334b | |
| ASCA-IgG1 (10 units increase) | 1.01 (0.95 - 1.08), 0.7144 | 1.01 (0.93 - 1.08), 0.8798b | ||||
| By anti-OmpC IgA | ||||||
| Anti-OmpC IgA (binary variable) | Low, 104 | 62 | 150 | 0.41 (0.32 - 0.53) | ||
| High, 31 | 22 | 53 | 0.42 (0.27 - 0.63) | 1.01 (0.62 - 1.64), 0.9673 | 0.97 (0.56 - 1.69), 0.9217c | |
| Anti-OmpC IgA1 (10 units increase) | 0.98 (0.85 - 1.12), 0.7633 | 0.96 (0.82 - 1.12), 0.6250c | ||||
| By anti-CBir1 IgG | ||||||
| Anti-CBir1 IgG (binary variable) | Low, 101 | 50 | 153 | 0.33 (0.25 - 0.43) | ||
| High, 34 | 34 | 50 | 0.68 (0.49 - 0.95) | 2.08 (1.35 - 3.22), 0.0010 | 2.06 (1.28 - 3.33), 0.0032d | |
| Anti-CBir1 IgG1 (10 units increase) | 1.06 (0.99 - 1.13), 0.0982 | 1.05 (0.97 - 1.12), 0.2146d | ||||
| By anti-A4Fla2 IgG | ||||||
| Anti-A4Fla2 IgG (binary variable) | Low, 87 | 47 | 137 | 0.34 (0.26 - 0.46) | ||
| High, 48 | 37 | 66 | 0.56 (0.41 - 0.78) | 1.64 (1.07 - 2.53), 0.0238 | 1.55 (0.95 - 2.52), 0.0789e | |
| Anti-A4Fla2 IgG1 (10 units increase) | 1.07 (1.00 - 1.14), 0.0490 | 1.06 (0.98 - 1.14), 0.1528e | ||||
| By anti-FlaX IgG | ||||||
| Anti-FlaX IgG (binary variable) | Low, 67 | 36 | 103 | 0.35 (0.25 - 0.48) | ||
| High, 68 | 48 | 100 | 0.48 (0.36 - 0.64) | 1.38 (0.89 - 2.12), 0.1471 | 1.22 (0.75 - 1.99), 0.4265f | |
| Anti-FlaX IgG1 (10 units increase) | 1.05 (0.99 - 1.12), 0.1062 | 1.05 (0.98 - 1.13), 0.1709f |
aAdjusted for age, gender, race, duration of disease, TNF, CD behavior, perianal involvement, disease location and obesity. bAdjusted for age, gender, race, duration of disease, steroid, tobacco use, TNF, CD behavior and disease location. cAdjusted for age, gender, race, duration of disease, steroid, TNF, vedolizumab, CD behavior, perianal involvement, UGI involvement, disease location and PPI. dAdjusted for age, gender, race, duration of disease, steroid, thiopurine, CD behavior, disease location, obesity and PPI. eAdjusted for age, gender, race, duration of disease, TNF, MTX, thiopurine, UGI involvement, disease location and PPI. fAdjusted for age, gender, race, duration of disease, steroid, tobacco use, thiopurine, TNF, vedolizumab, UST, CD behavior, perianal involvement and disease location. CDA: Crohn’s disease activity; RR: rate ratio; CI: confidence interval; TNF: tumor necrosis factor; UST: ustekinumab; MTX: methotrexate; UGI: upper gastrointestinal; PPI: proton pump inhibitor.